L-Aspartic acid
|
Basic information |
| Metabolite name | L-Aspartic acid |
 | HMDB0000191 |
 |
C00049 |
 |
5960 |
| Synonyms | Asparate; |
| No. of studies | 75 |
|
Basic information |
| Metabolite name | L-Aspartic acid |
| HMDB0000191 |
|
C00049 |
|
5960 |
| Synonyms | Asparate; |
| No. of studies | 75 |
|
Relationship between L-Aspartic acid and depression (count: 75) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M002 | Type1 | CUMS group vs. control group | Cerebral cortex | Sprague-Dawley rat | Down |
| Study M006 | Type1 | depressed group vs. control group | Plasma | Human | Up |
| Study M010 | Type4 | SSRI-treated responder group vs. non-responder group | Plasma | Human | Up |
| Study M018 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M018 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M019 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M022 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M025 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M030 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M031 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M045 | Type1 | CUMS group vs. control group | Peripheral blood mononuclear cell | Sprague-Dawley rat | Down |
| Study M071 | Type2 | CUMS + imipramine group vs. CUMS group | Hippocampus | C57BL/6N mouse | Up |
| Study M076 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M078 | Type1 | CORT model group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M078 | Type2 | CORT model + icariin group vs. CORT model group | Brain | Sprague-Dawley rat | Down |
| Study M096 | Type1 | CUMS group vs. control group | Prefrontal cortex | Wistar rat | Up |
| Study M100 | Type1 | CS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M1019 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M1023 | Type1 | CRS group vs. control group | Faece | C57BL/6 J mouse | Up |
| Study M1049 | Type1 | MDD group vs. control group | Serum | Human | Up |
| Study M107 | Type1 | Glu group vs. control group | PC12 cell | Rat | Up |
| Study M107 | Type1 | Glu group vs. control group | PC12 cell medium | Rat | Down |
| Study M107 | Type1 | CORT group vs. control group | PC12 cell | Rat | Up |
| Study M1096 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M1096 | Type2 | CUMS + low dose of Xiaoyao Pills group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M1096 | Type2 | CUMS + high dose of Xiaoyao Pills group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M1096 | Type2 | CUMS + fluoxetine group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M1096 | Type2 | CUMS + middle dose of Xiaoyao Pills group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M115 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M129 | Type3 | venlafaxine group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M130 | Type2 | CSDS + venlafaxine group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M131 | Type1 | LH group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M131 | Type1 | SD group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M146 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M146 | Type2 | CUMS + high dose of SSO group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M146 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M146 | Type2 | CUMS + middle dose of SSO group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M164 | Type1 | depressed group vs. control group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M165 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M181 | Type3 | venlafaxine group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M204 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Down |
| Study M207 | Type1 | depressed group vs. control group | Faece | Kunming mouse | Down |
| Study M208 | Type1 | GCI model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M454 | Type1 | vascular depression model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M458 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M463 | Type3 | venlafaxine group vs. control group | Prefrontal cortex | C57BL/6J mouse | Up |
| Study M478 | Type3 | ketamine group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M479 | Type1 | diabetic depression group vs. control group | Hypothalamus | Wistar rat | Down |
| Study M479 | Type1 | diabetic depression group vs. control group | Prefrontal cortex | Wistar rat | Down |
| Study M511 | Type1 | Susceptible group vs. control group | Hippocampus | Wistar/ST rat | Down |
| Study M519 | Type1 | susceptible group vs. control group | Prefrontal cortex | C57BL/6N mouse | Down |
| Study M522 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Unknown |
| Study M536 | Type1 | naturally-occurring depression group vs. control group | Cerebrospinal fluid | Cynomolgus monkey | Up |
| Study M547 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M555 | Type1 | FMT group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M571 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Down |
| Study M573 | Type1 | CSDS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M577 | Type1 | male depression group vs. male control group, aged 30-39 | Urine | Human | Unknown |
| Study M578 | Type1 | restraint stress offspring group vs. control offspring group | Hippocampus | Sprague-Dawley rat | Up |
| Study M583 | Type2 | PSD group, after vs. before fluoxetine treatment | Hippocampus | Sprague-Dawley rat | Down |
| Study M594 | Type1 | CRS group vs. control group | Entorhinal cortex | C57BL/6 mouse | Up |
| Study M595 | Type1 | CRS group vs. control group | Nucleus accumbens | C57BL/6J mouse | Down |
| Study M616 | Type1 | CUMS group vs. control group | Olfactory bulb | Sprague-Dawley rat | Up |
| Study M636 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M680 | Type2 | 5-fluorouracil + FMT group vs. 5-fluorouracil + sham FMT group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M720 | Type1 | CUMS susceptible group vs. control group | Habenula | Sprague-Dawley rat | Down |
| Study M732 | Type1 | CUMS + high dose of propionate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Unknown |
| Study M756 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M770 | Type4 | responder group vs. non-responder group | Serum | C57BL/6 mouse | Up |
| Study M775 | Type1 | prenatal stress group vs. control group | Brain | Swiss Webster mouse | Down |
| Study M779 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M788 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M791 | Type1 | CUMS group vs. control group | Cecum | Sprague-Dawley rat | Down |
| Study M828 | Type1 | ultrasonic radiation group vs. control group | Frontal cortex | Wistar rat | Down |
| Study M828 | Type2 | ultrasonic radiation + intraperitoneally clomipramine group vs. ultrasonic radiation group | Frontal cortex | Wistar rat | Up |
| Study M828 | Type2 | ultrasonic radiation + intranasally clomipramine group vs. ultrasonic radiation group | Hippocampus | Wistar rat | Up |
| Study M844 | Type1 | CORT group vs. control group | PC12 cell | Rat | Up |
| Study M850 | Type1 | reserpine group vs. control group | Brain | C57BL/6 mouse | Down |
| Study M870 | Type1 | CRS group vs. control group | Brain | C57BL/6 mouse | Down |
| Study M870 | Type2 | CRS + middle dose of Jia Wei Xiao Yao San group vs. CRS group | Brain | C57BL/6 mouse | Down |
| Study M881 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M882 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M912 | Type1 | CUMS group vs. control group | Serum | ICR mouse | Up |
| Study M921 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Up |
| Study M935 | Type3 | tianeptine group vs. control group | Hippocampus | Wistar rat | Up |
| Study M943 | Type1 | CUMS group vs. control group | Liver | ICR mouse | Down |
| Study M943 | Type2 | CUMS + middle dose of Acanthopanax senticosus Harms group vs. CUMS group | Liver | ICR mouse | Up |
| Study M943 | Type2 | CUMS + high dose of Acanthopanax senticosus Harms group vs. CUMS group | Liver | ICR mouse | Up |
| Study M953 | Type1 | CRS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M965 | Type1 | CUMS depression group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M966 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M966 | Type2 | CUMS + Xiaoyao San group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M966 | Type2 | CUMS + venlafaxine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M981 | Type2 | Abeta oligomer + involuntary and voluntary running + acousto-optic stimulation group vs. Abeta oligomer group | Serum | ICR mouse | Up |
| Study M981 | Type2 | Abeta oligomer + involuntary and voluntary running group vs. Abeta oligomer group | Serum | ICR mouse | Up |